Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 8Thoracic 5Head & Neck 5Gastrointestinal 4Gynecologic 3Genitourinary 3Lymphoid 2Breast 2Other solid neoplasm 1CNS 1

Conditions

Glioblastoma 3Ovarian Neoplasms 1Melanoma 1Lymphoma 1Lung Neoplasms 1Head and Neck Neoplasms 1Glioma 1Colorectal Neoplasms 1

Interventions

Radiosurgery 22Nivolumab 21Ipilimumab 19pembrolizumab 15Temozolomide 11dabrafenib 10binimetinib 10encorafenib 8Cyclophosphamide 8trametinib 7Magnetic Resonance Spectroscopy 7Bevacizumab 6fludarabine 5cobimetinib 5Specimen Handling 5CTLA-4 Antigen 5fludarabine phosphate 3aldesleukin 3Vemurafenib 3Thalidomide 3Paclitaxel 3Oxaliplatin 3Interleukin-2 3Gemcitabine 3Drug Therapy 3Carboplatin 3130-nm albumin-bound paclitaxel 3ulixertinib 2tovorafenib 2relatlimab 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Melanoma × epacadostat × CNS × Clear all
NCT02327078 2025-08-14

A Study of the Safety, Tolerability, and Efficacy of Epacadostat Administered in Combination With Nivolumab in Select Advanced Cancers (ECHO-204)

Incyte Corporation

Phase 1/2 Completed
307 enrolled 27 charts
CNSDermatologicGastrointestinalGynecologicHead & NeckLymphoidThoracic

Glioblastoma, Head and Neck Neoplasms, Lung Neoplasms, Lymphoma, Melanoma, Ovarian Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡